Guardant Health (NASDAQ:GH) Stock Jumps 4.8% - Still a Buy?

Guardant Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Guardant Health shares rose 4.8% to $152.12, though trading volume was 81% below its average.
  • Analysts have a consensus “Moderate Buy” rating and an average price target of $190.88; 24 rate the stock Buy, one Strong Buy, and one Sell.
  • Quarterly results beat expectations: Guardant reported a $0.29 loss per share versus the estimated $0.75 loss, while revenue of $360.98 million grew 36.1% year over year.
  • MarketBeat previews the top five stocks to own by December 1st.

Guardant Health, Inc. (NASDAQ:GH - Get Free Report)'s stock price was up 4.8% on Thursday. The stock traded as high as $155.97 and last traded at $152.12. Approximately 414,237 shares traded hands during trading, a decline of 81% from the average session volume of 2,205,497 shares. The stock had previously closed at $145.14.

Wall Street Analyst Weigh In

GH has been the subject of a number of research reports. The Goldman Sachs Group restated a "buy" rating and set a $210.00 target price on shares of Guardant Health in a research report on Friday, July 31st. TD Cowen reiterated a "buy" rating on shares of Guardant Health in a research report on Wednesday. Roth Capital assumed coverage on shares of Guardant Health in a research note on Thursday, October 22nd. They set a "buy" rating and a $200.00 price objective for the company. Sanford C. Bernstein restated an "outperform" rating and set a $210.00 price objective on shares of Guardant Health in a research report on Thursday, September 10th. Finally, UBS Group increased their target price on Guardant Health from $175.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Guardant Health currently has a consensus rating of "Moderate Buy" and an average target price of $190.88.

View Our Latest Stock Analysis on GH

Guardant Health Price Performance

The company's 50-day moving average is $167.58 and its 200-day moving average is $133.48. The firm has a market capitalization of $20.30 billion, a price-to-earnings ratio of -40.77 and a beta of 1.67.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.46. The company had revenue of $360.98 million during the quarter, compared to analyst estimates of $350.72 million. During the same quarter last year, the business earned ($0.74) EPS. The firm's revenue for the quarter was up 36.1% compared to the same quarter last year. Sell-side analysts anticipate that Guardant Health, Inc. will post -3.28 earnings per share for the current year.

Insider Activity

In related news, Director Steve Krognes sold 6,674 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total value of $1,172,888.76. Following the sale, the director owned 7,906 shares of the company's stock, valued at $1,389,400.44. This trade represents a 45.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Darya Chudova sold 7,738 shares of the company's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total transaction of $1,377,364.00. Following the completion of the transaction, the chief technology officer owned 70,635 shares of the company's stock, valued at approximately $12,573,030. This trade represents a 9.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 53,224 shares of company stock worth $9,116,546 over the last ninety days. Insiders own 5.60% of the company's stock.

Hedge Funds Weigh In On Guardant Health

Hedge funds have recently modified their holdings of the company. Groupama Asset Managment bought a new position in shares of Guardant Health in the third quarter valued at $2,764,000. The Manufacturers Life Insurance Company acquired a new stake in Guardant Health during the 2nd quarter worth about $208,592,000. William Blair Investment Management LLC acquired a new stake in Guardant Health during the 2nd quarter worth about $196,737,000. PointState Capital LP acquired a new stake in Guardant Health during the 3rd quarter worth about $176,851,000. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its stake in Guardant Health by 443,025.0% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 709,000 shares of the company's stock valued at $126,457,000 after acquiring an additional 708,840 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Guardant Health

(Get Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Guardant Health Right Now?

Before you consider Guardant Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.

While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines